There currently are no uniformly accepted clinical, neuroimaging, or laboratory outcome measures for clinical trials for the treatment of HIV associated neurocognitive disorders (HAND). The goals and objectives of this Core are: 1) to provide the resources necessary to continue a clinical cohort of well-characterized HIV+ and demographically-matched HIV- individuals for studies evaluating new outcome measures and surrogate markers for clinical trials of HAND, 2) to liaise with other NIMH Centers or other funded IPCPs involved in NeuroAIDs therapeutic work to help identify potential candidate agents, 3) to provide the resources necessary to design and conduct small pilot studies to evaluate potential novel compounds to treat HAND, 4) to maintain a data infrastructure to allow for efficient querying of clinical and laboratory data, 5) to provide statistical support for studies involving the Center Grant resources, 6) to provide a resource for linkage with ongoing Neuro-AIDS trial consortia. The Clinical Outcomes Core provides support for a cohort of 150 HIV+ and 50 HIV- individuals which is used to evaluate both neurocognitive and novel functional assessments. Stored CSF and blood specimens from cohort participants are used to validate surrogate markers. Participants with a well characterized HAND stage from the Clinical Outcomes Cohort are used for developmental projects. The Core also evaluates safety, tolerability, and efficacy outcome measures for new compounds for the treatment of HAND. Thus, the Core provides a service to develop improved outcome measures for use in clinical trials, and obtains preliminary data for candidate drugs of safety and tolerability. The Core will also obtain data to determine the sample size needed for larger, confirmatory studies of efficacy.
HIV/AIDS is a major threat to global health and urban America, and HIV-associated-neurocognitive dysfunction remains prevalent even in H/V^RT-treated people. Our research suggests that one of the drivers for this is sustained inflammation within the brain. Our Center has helped to coordinate and catalyze scientific and clinical resources at JHU to generate novel approaches to therapy.
|Saylor, Deanna; Dickens, Alex M; Sacktor, Ned et al. (2016) HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment. Nat Rev Neurol 12:234-48|
|Sacktor, Ned; Skolasky, Richard L; Seaberg, Eric et al. (2016) Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology 86:334-40|
|Anderson, Brian A; Kronemer, Sharif I; Rilee, Jessica J et al. (2016) Reward, attention, and HIV-related risk in HIV+ individuals. Neurobiol Dis 92:157-65|
|Fazeli, Pariya L; Moore, David J; Franklin, Donald R et al. (2016) Lower CSF AÎ² is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Curr HIV Res 14:324-30|
|Ramos, FÃ©lix M; Delgado-VÃ©lez, Manuel; Ortiz, Ãngel L et al. (2016) Expression of CHRFAM7A and CHRNA7 in neuronal cells and postmortem brain of HIV-infected patients: considerations for HIV-associated neurocognitive disorder. J Neurovirol 22:327-35|
|Kumar, Vivek; Bonifazi, Alessandro; Ellenberger, Michael P et al. (2016) Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment. J Med Chem 59:7634-50|
|Buchanan, Erin L; Espinoza, Diego A; McAlexander, Melissa A et al. (2016) SAMHD1 transcript upregulation during SIV infection of the central nervous system does not associate with reduced viral load. Sci Rep 6:22629|
|Elgogary, Amira; Xu, Qingguo; Poore, Brad et al. (2016) Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A 113:E5328-36|
|Clifford, David B; Vaida, Florin; Kao, Yu-Ting et al. (2015) Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology 84:241-50|
|Witwer, Kenneth W; Buchanan, Erin L; Myers, Stephanie L et al. (2015) miRNAs and SAMHD1 regulation in vitro and in a model of HIV CNS disease. J Neuroinflammation 12:159|
Showing the most recent 10 out of 126 publications